Targeting CD44 and other pleiotropic co-receptors as a means for broad inhibition of tumor growth and metastasis

Abstract

Although progress has been made in the treatment of cancer, particularly for the four major types of cancers affecting the lungs, colon, breast and prostate, resistance to cancer treatment often emerges upon inhibition of major signaling pathways, which leads to the activation of additional pathways as a last-resort survival mechanism by the cancer cells. This signaling plasticity provides cancer cells with a level of operational freedom, reducing treatment efficacy. Plasticity is a characteristic of cancer cells that are not only able to switch signaling pathways but also from one cellular state (differentiated cells to stem cells or vice versa) to another. It seems implausible that the inhibition of one or a few signaling pathways of heterogeneous and plastic tumors can sustain a durable effect. We propose that inhibiting molecules with pleiotropic functions such as cell surface co-receptors can be a key to preventing therapy escape instead of targeting bona fide receptors. Therefore, we ask the question whether co-receptors often considered as "accessory molecules" are an overlooked key to control cancer cell behavior.

Keywords: CD44; Cancer; Co-receptors; Metastasis; Pleiotropicity.

Fig. 1

Schematic illustration of co-receptors with their corresponding partner receptors. Figure created with BioRender.com

Fig. 2

Schematic representation of the CD44 family of proteins, the gene structure and the expression pattern of specific isoforms. Figure created with BioRender.com